Radiomics in Meningiomas: Pathological and Biomolecular Correlation

Radiomics, a burgeoning field in medical imaging, leverages advanced computational techniques to extract high-dimensional data from standard imaging modalities, offering profound insights into tumor characterization. In the context of meningiomas radiomics presents a promising frontier for enhancing diagnostic accuracy, prognostic assessment, and therapeutic planning. Primarily, radiomics may facilitate the non-invasive differentiation of meningioma subtypes by analyzing texture, shape, and intensity features derived from MRI and CT scans. Such differentiation is critical as various subtypes exhibit distinct biological behaviors and clinical outcomes. Furthermore, radiomics can predict molecular markers and genetic mutations, such as the presence of the TERT promoter mutation, which correlates with more aggressive tumor behavior. This predictive capability aids in stratifying patients for personalized treatment regimens. Another pivotal application is in prognosis. Radiomic features have been linked to recurrence rates and survival outcomes, enabling clinicians to identify high risk patients who may benefit from more aggressive treatment and closer monitoring. Additionally, radiomics offers potential in treatment response assessment. By evaluating changes in imaging features over time, it is possible to monitor the efficacy of therapies, such as surgery, radiation, and emerging targeted therapies, thus facilitating timely modifications to treatment plans. In conclusion, radiomics stands as a transformative tool in the realm of meningioma management, enhancing the precision of diagnosis, prognosis, and treatment response monitoring. Continued advancements and integration of radiomic techniques into clinical practice hold promise for improving patient outcomes and personalizing meningioma care.